by @JTC_PALIdev | Jan 22, 2025 | Press Releases
Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
by @JTC_PALIdev | Jan 16, 2025 | Press Releases
Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial...
by @JTC_PALIdev | Jan 3, 2025 | Press Releases
Carlsbad, CA, Jan. 03, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients...
by @JTC_PALIdev | Dec 17, 2024 | Press Releases
Carlsbad, CA, Dec. 17, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune,...
by @JTC_PALIdev | Dec 13, 2024 | Press Releases
Carlsbad, CA, Dec. 13, 2024 — Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory,...
by @JTC_PALIdev | Dec 12, 2024 | Press Releases
Carlsbad, CA, Dec. 12, 2024 — Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory,...
